Featured Research

from universities, journals, and other organizations

Gene's Activity Points To More Lethal Subtype Of Acute Myeloid Leukemia

Date:
July 12, 2007
Source:
Ohio State University
Summary:
A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy. The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer.

A new study shows that the activity of a particular gene can identify people who have a more lethal form of acute myeloid leukemia, singling out those patients who should receive more intense therapy.

The gene, called ERG (for ETS-related gene), has also been linked to chronic leukemia and to breast and prostate cancer.

The findings apply to acute myeloid leukemia (AML) patients with leukemia cells that have normal-looking chromosomes, a feature that occurs in about half of AML patients.

Among these patients, those with leukemia cells showing high ERG activity are almost six times more likely to relapse or die within five years than are patients with low ERG expression following standard therapy.

The Cancer and Leukemia Group B study was initiated by researchers at the Ohio State University Comprehensive Cancer Center, and their findings were published online in the Journal of Clinical Oncology.

“Our study shows that high ERG activity predicts a poor prognosis in these patients, even when other molecular markers are taken into consideration,” says first author Guido Marcucci, associate professor of internal medicine and an AML specialist at Ohio State's James Cancer Hospital and Solove Research Institute.

“The findings mean that these patients require a stem-cell transplant or other aggressive therapy, and that patients with low ERG activity can be treated using standard therapy.”

The research confirms a 2005 study led by the same Ohio State researchers in a completely independent set of patients, Marcucci says.

“Both studies together further refine the molecular classification of AML in this group of patients and should help us improve treatment outcomes,” says principal investigator Clara D. Bloomfield, professor of internal medicine, and an internationally recognized specialist in AML.

About 13,400 new cases of AML are expected this year, and a little more than half will have leukemia cells with normal-looking chromosomes. The rest will have chromosomes that show distinctive damage. In these patients, the type of damage helps doctors determine the best therapy and an individual's prognosis.

In 2005, Bloomfield, Marcucci and colleagues were the first to show that high ERG levels predicted a poor response to therapy in patients whose cancer cells have normal-looking chromosomes.

The present study was designed to verify that finding in a separate group of 76 AML patients under 60 years of age. It also took into consideration other genetic markers that signal whether the disease will respond well or poorly to standard therapy.

“We showed very similar results in this completely separate group of patients,” Marcucci says. “After two years, only 29 percent of patients with high ERG were disease-free and alive versus 53 percent of patients with low ERG activity.”

Funding from the National Cancer Institute and The Coleman Leukemia Research Foundation supported this research.


Story Source:

The above story is based on materials provided by Ohio State University. Note: Materials may be edited for content and length.


Cite This Page:

Ohio State University. "Gene's Activity Points To More Lethal Subtype Of Acute Myeloid Leukemia." ScienceDaily. ScienceDaily, 12 July 2007. <www.sciencedaily.com/releases/2007/07/070709171545.htm>.
Ohio State University. (2007, July 12). Gene's Activity Points To More Lethal Subtype Of Acute Myeloid Leukemia. ScienceDaily. Retrieved August 23, 2014 from www.sciencedaily.com/releases/2007/07/070709171545.htm
Ohio State University. "Gene's Activity Points To More Lethal Subtype Of Acute Myeloid Leukemia." ScienceDaily. www.sciencedaily.com/releases/2007/07/070709171545.htm (accessed August 23, 2014).

Share This




More Health & Medicine News

Saturday, August 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Two US Ebola Patients Leave Hospital Free of the Disease

Two US Ebola Patients Leave Hospital Free of the Disease

AFP (Aug. 21, 2014) Two American missionaries who were sickened with Ebola while working in Liberia and were treated with an experimental drug are doing better and have left the hospital, doctors say on August 21, 2014. Duration: 01:05 Video provided by AFP
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins